id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-0576-0003,FDA,FDA-2013-D-0576,Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Extension of Comment Period,Notice,Notice of Availability,2013-11-20T05:00:00Z,2013,11,2013-11-20T05:00:00Z,2014-05-10T03:59:59Z,2014-05-13T14:34:04Z,2013-27769,0,0,090000648148ba3d
FDA-2013-D-0576-0001,FDA,FDA-2013-D-0576,Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products; Availability,Notice,Notice of Availability,2013-07-02T04:00:00Z,2013,7,2013-07-02T04:00:00Z,2013-11-23T04:59:59Z,2014-01-31T02:02:34Z,2013-15797,0,0,09000064813517c4
FDA-2013-D-0576-0002,FDA,FDA-2013-D-0576,Draft Guidance for Industry:  Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products,Other,Guidance,2013-07-02T04:00:00Z,2013,7,2013-07-02T04:00:00Z,,2024-11-12T05:16:03Z,,1,0,0900006481350f90